
USD
$0.00
(0.00%
)At Close (As of Nov 26, 2025)
$146.18B
Market Cap
14.95
P/E Ratio
1.72
EPS
$27.21
52 Week High
$19.83
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $42B |
| Total Revenue | $64B |
| Cost Of Revenue | $22B |
| Costof Goods And Services Sold | $22B |
| Operating Income | $16B |
| Selling General And Administrative | $11B |
| Research And Development | $11B |
| Operating Expenses | $25B |
| Investment Income Net | - |
| Net Interest Income | -$2.5B |
| Interest Income | $545M |
| Interest Expense | $3.1B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $7B |
| Income Before Tax | $8B |
| Income Tax Expense | -$28M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $8.1B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $11B |
| Ebitda | $18B |
| Net Income | $8B |
| Field | Value (USD) |
|---|---|
| Total Assets | $213B |
| Total Current Assets | $50B |
| Cash And Cash Equivalents At Carrying Value | $1B |
| Cash And Short Term Investments | $1B |
| Inventory | $11B |
| Current Net Receivables | $15B |
| Total Non Current Assets | $163B |
| Property Plant Equipment | $21B |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $55B |
| Intangible Assets Excluding Goodwill | $55B |
| Goodwill | $69B |
| Investments | - |
| Long Term Investments | $2.2B |
| Short Term Investments | $19B |
| Other Current Assets | $4.3B |
| Other Non Current Assets | - |
| Total Liabilities | $125B |
| Total Current Liabilities | $43B |
| Current Accounts Payable | $5.6B |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $7.3B |
| Total Non Current Liabilities | $82B |
| Capital Lease Obligations | - |
| Long Term Debt | $57B |
| Current Long Term Debt | $6.9B |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $67B |
| Other Current Liabilities | $29B |
| Other Non Current Liabilities | $14B |
| Total Shareholder Equity | $88B |
| Treasury Stock | - |
| Retained Earnings | $117B |
| Common Stock | $480M |
| Common Stock Shares Outstanding | $5.7B |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $13B |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $7B |
| Capital Expenditures | $2.9B |
| Change In Receivables | - |
| Change In Inventory | -$854M |
| Profit Loss | - |
| Cashflow From Investment | $2.7B |
| Cashflow From Financing | -$17B |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | $9.5B |
| Dividend Payout Common Stock | $9.5B |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | $0 |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $8.1B |
| Field | Value (USD) |
|---|---|
| Gross Profit | $42B |
| Total Revenue | $64B |
| Cost Of Revenue | $22B |
| Costof Goods And Services Sold | $22B |
| Operating Income | $16B |
| Selling General And Administrative | $11B |
| Research And Development | $11B |
| Operating Expenses | $25B |
| Investment Income Net | - |
| Net Interest Income | -$2.5B |
| Interest Income | $545M |
| Interest Expense | $3.1B |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $7B |
| Income Before Tax | $8B |
| Income Tax Expense | -$28M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $8.1B |
| Comprehensive Income Net Of Tax | - |
| Ebit | $11B |
| Ebitda | $18B |
| Net Income | $8B |
| Field | Value |
|---|---|
| Ex Dividend Date | 2025-11-07 |
| Declaration Date | 2025-10-09 |
| Record Date | 2025-11-07 |
| Payment Date | 2025-12-01 |
| Amount | 0.43 |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - GENERAL
Pfizer Inc. is a preeminent global pharmaceutical and biotechnology firm based in New York City, with a storied legacy of innovation since its founding in 1849. The company is renowned for its diverse therapeutic portfolio, which spans immunology, oncology, and cardiology, and is supported by a robust pipeline of groundbreaking treatments. Notably, Pfizer's rapid development of the COVID-19 vaccine underscored its agility in research and commitment to addressing urgent public health needs. Through strategic collaborations and ongoing investment in cutting-edge research, Pfizer is poised to sustain its leadership position in the healthcare sector while continuing to improve health outcomes worldwide.